Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapaquistat acetate versus placebo in adults with hypercholesterolemia
NL-OMON31031Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lapaquistat in hypercholesterolemia (3 arms), sponsored by Takeda. Primary endpoint: Fasting plasma LDL cholesterol. Planned start Aug 2007; status: not yet recruiting.
02
Drugs
lapaquistat
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON31031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31031.